ATGen operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares ATGen with three other
companies in this sector in South Korea:
sales of 7.71 billion Korean Won [US$6.48 million]
of which 54%
was Cooperation research development),
(7.70 billion Korean Won [US$6.47 million]
Pangen Biotech Inc
(5.68 billion Korean Won [US$4.77 million]
of which 75%
ATGen reported sales of 6.27 billion Korean Won (US$5.27 million)
December of 2018.
increase of 29.8%
versus 2017, when the company's sales were 4.83 billion Korean Won.
Despite this increase, sales are still
below the level achieved in 2016, when ATGen
reported sales of 6.88 billion Korean Won.